

Department of Planning and Budget 2020 Fiscal Impact Statement

1. Bill Number: SB270S1

House of Origin	<input type="checkbox"/> Introduced	<input checked="" type="checkbox"/> Substitute	<input type="checkbox"/> Engrossed
Second House	<input type="checkbox"/> In Committee	<input type="checkbox"/> Substitute	<input type="checkbox"/> Enrolled

2. Patron: Bell

3. Committee: Education and Health

4. Title: Practice of pharmacy; regulation by Board of Pharmacy; report.

5. Summary: The substitute bill provides that only outsourcing facilities may compound such drugs; currently, both pharmacies and outsourcing facilities may compound such drugs. The bill requires that the Board of Pharmacy shall report annually by December 1 to the Chairmen of the Senate Committee on Education and Health and the House Committee on Health, Welfare and Institutions on (i) the number of pharmacies and outsourcing facilities permitted or registered by the Board that perform sterile compounding in Virginia or ship sterile compounded drugs into Virginia and (ii) the name of any pharmacies or outsourcing facilities that received disciplinary action for a violation of law or regulation related to compounding.

6. Budget Amendment Necessary: See item #8.

7. Fiscal Impact Estimates: Minimal, see item #8.

8. Fiscal Implications: Any increase in workload associated with the reporting requirement can be absorbed within existing resources by the Board. Any impact the provisions of the bill may have on the Department of Corrections for drug procurement are indeterminate.

9. Specific Agency or Political Subdivisions Affected: The Department of Health, the Department of Health Professions, and the Department of Corrections.

10. Technical Amendment Necessary: None.

11. Other Comments: No.